Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

David A. Hyman, MD, JD, on Inclusive Shared Savings

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement




Jul
28
Today In Oncology
Dabrafenib Plus Trametinib Improves Progression-Free Survival in BRAF V600E-Positive Differentiated Thyroid Cancer
Relapsed or Refractory Multiple Myeloma: Early-Phase Trial Investigates Novel Bispecific Antibody
Emergency Department Cancer Diagnosis Associated With Higher Mortality Across 16 Cancer Types
Avatrombopag Manages Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancer
Proton Pump Inhibitor, Antibiotic Exposure Linked to Worse Durvalumab Outcomes in Unresectable Stage III NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo